<DOC>
	<DOCNO>NCT01101347</DOCNO>
	<brief_summary>The purpose study evaluate safety performance Surpass Aneurysm-Embolization System .</brief_summary>
	<brief_title>A Feasibility Study Surpass Aneurysm-Embolization System Intracranial Arteries</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<criteria>Subject understand nature procedure provide write informed consent . Subject willing return investigational site thirty day six month followup evaluation . Age 18 year 80 year . Subject nonruptured saccular , fusiform intracranial aneurysm arise parent vessel diameter &gt; 2mm &lt; 6mm . Pregnancy Enrollment another trial Allergy contraindication aspirin , clopidogrel , heparin , local general anesthesia History life threaten allergy contrast dye . Major surgery within previous 30 day plan next 90 day enrollment date . Severe neurological deficit render patient incapable living independently Dementia psychiatric problem prevent patient completing require follow Comorbid condition may limit survival le one year Subject anatomy appropriate endovascular treatment due severe intracranial vessel tortuosity stenosis , intracranial vasospasm responsive medical therapy . Subject intracranial mass ( tumor ( except meningioma ) , abscess , infection ) , undergo radiation therapy carcinoma sarcoma head neck region . Subject history bleed diathesis coagulopathy , international normalize ratio ( INR ) great 1.5 , refuse blood transfusion . Subject serum creatinine level great 2.0 mg/dL ( within 7 day procedure ) investigator determines restricts use contrast agent . Subject previously implant intracranial stent associate symptomatic distribution within past 12 week prior enrollment date Stenting , angioplasty , endarterectomy extracranial ( carotid vertebral artery ) intracranial artery within 30 day prior enrollment date Subject previously implant carotid stent associate symptomatic distribution within past 12 week prior enrollment date Subject uncontrolled atrial fibrillation know cardiac disorder likely associate cardioembolic symptom . Subject subarachnoid hemorrhage within 12 week prior enrollment date . Subject resistance ASA and/or Clopidogrel . Subject two aneurysm associate distribution unless device use treat aneurysm . Subject nontreated arteriovenous malformation ( AVM ) territory target aneurysm . Target aneurysm expect require one device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>